Sangamo Therapeutics, Inc. stock is down -1.67% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 23 December’s closed higher than November. 25% of analysts rate it a buy.
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection.